MAPT and Alzheimer disease: From a recent autopsy-confirmed cohort, Kim et al[75] found that the TREM2 variant was more frequently associated with non-amnestic clinical syndromes and contributed to clinical and pathologic AD heterogeneity by altering the distribution of neurofibrillary degeneration and tau-dependent microglial dystrophy, resulting in hippocampal-sparing and non-amnestic AD phenotypes.